Onco-Summaries: Daily Oncology Updates at a Glance

02/07/2026

---

• Roche's Divarasib demonstrates superiority over approved KRAS G12C Inhibitors in Phase 3 NSCLC trial

---

Roche's Divarasib demonstrates superiority over approved KRAS G12C Inhibitors in Phase 3 NSCLC trial (Ref)

Roche's Phase 3 Krascendo 1 study of divarasib (next-generation KRAS G12C inhibitor) demonstrated statistically significant improvements in both progression-free and overall survival vs approved first generation KRAS G12C inhibitors sotorasib or adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC).

Safety profile consistent with prior data; no new signals

Detailed results will be presented at an upcoming medical meeting and submitted to health authorities for regulatory review

Return to Top